 Gas permeable bioreactor and method of use |
| OF THE PREFERRED EMBODIMENTS Like numbered apparatus elements in FIGS. 1-11 are the same. R... |
|
| Method for treating diseases of the inner ear using adamantane derivatives |
| OF THE INVENTION As already mentioned, the use of adamantane derivatives is possible or ... |
|
| Polyalkylene oxide-containing urethane polyols with sulphonic acid groups |
| What is claimed is: 1. Sulphonic acid group-containing polyalkylene oxide-containing urethane ... |
|
| Herpes treatment |
| I claim: 1. A method for the control of herpes virus infections in man which comprises contacting ... |
|
| Dense star polymers and dendrimers |
| OF ILLUSTRATIVE EMBODIMENTS In the dense star polymers of the present invention, the core is ... |
|
| Glycerin derivatives and inhibition of blood PAF |
| OF THE INVENTION The glycerine derivatives of the invention are compounds of the formula ##STR3## ... |
|
| Oligonucleotide derivatives and production thereof |
| Gist In view of the state of the art as described above, the present inventors have developed an ... |
|
| Process for synthesizing macrocyclic chelates |
| The invention is a process for synthesizing a 12 membered ring tetraaza macromolecule. The process ... |
|
| Immunoconjugates joined by thioether bonds having reduced toxicity and improved selectivity |
| I claim: 1. A method for producing a 1:1 protein:anitbody tioether-linked immunoconjugate as a ... |
|
| Compositions for photodynamic therapy |
| I claim: 1. A pharmaceutical composition useful for photodynamic therapy which composition contains,... |
|
|
Compositions and methods for drug delivery using pH sensitive molecules
| Details |
Inventors: Wolff, Jon A.; Hagstrom, James E.; Rozema, David B.; Monahan, Sean D.; Budker, Vladimir G.;
Assignee: Mirus Bio Corporation (Madison, WI)
Primary Examiner: Guzo; David
Assistant Examiner:
Attorney, Agent or Firm: Johnson; Mark K. Ekena; Kirk
A system relating to the delivery of desired compounds (e.g., drugs and nucleic acids) into cells using pH-sensitive delivery systems. The system provides compositions and methods for the delivery and release of a compound to a cell. |
|
DETAILED DESCRIPTION We claim: 1.
A process for transfecting a nucleic acid into a cell in vivo, comprising: a) attaching a membrane activity inhibitor to a membrane active peptide via a labile linkage, wherein the inhibitor is detached within the cell; b) adding the peptide to a solution containing the nucleic acid; c) delivering the peptide and nucleic acid to the cell, wherein the peptide and the nucleic acid are endocytosed; and, d) transfecting the cell.
2.
The process of claim 1 wherein the peptide consists of pardaxin.
3.
The process of claim 1 wherein the peptide consists of KL3.
4.
The process of claim 1 wherein the peptide consists of magainin.
5.
The process of claim 1 wherein the labile linkage is selected from the group consisting of pH-labile, very pH labile, and extremely pH-labile.
6.
The process of claim 1 wherein the labile linkage is selected from the group consisting of disulfide, acetal, ketal, enol ether, enol esters amide, imine, imminium, enamine, allyl ether, silazane, and silyl enol ether bonds.
7.
The process of claim 1 wherein the labile linkage is selected from the group consisting of dials, diazo, ester, sulfone, and silicon-carbon bonds.
8.
A process for transfecting a nucleic acid into a cell in vivo, comprising: a) attaching a reversible labile membrane activity inhibitor to a melittin peptide wherein the inhibitor is detached upon association with the cell; b) adding the peptide to a solution containing the nucleic acid; c) contacting the peptide and nucleic acid with the cell, wherein the peptide and nucleic acid are endocytosed; and, d) transfecting to cell.
9.
A process for transfecting a nucleic acid into a cell in vivo, comprising: a) attaching a membrane activity inhibitor to a membrane active polymer via a labile linkage wherein the inhibitor is detached upon association with the cell; b) adding the membrane active polymer to a solution containing the nucleic acid; c) contacting the membrane active polymer and nucleic acid with the cell wherein the membrane active polymer and the nucleic acid are endocytosed; and, d) transfecting the cell
|
|
Gene Therapy 
